Chemerin Rs17173608 Research Articles

Association of RARRES2 rs17173608 gene polymorphism and serum Chemerin with acute myocardial infarction and its risk factors: A case-control study in an Iranian population

ObjectiveThe adipokine Chemerin and the retinoic acid receptor responder 2 (RARRES2) gene have been associated with an increased incidence of obesity, insulin resistance, endothelial dysfunction, type 2 diabetes mellitus, and coronary artery disease. The impact of RARRES2 rs17173608 gene polymorphism on acute myocardial infarction and Chemerin levels has not yet been entirely elucidated. This study aimed to assess the association of RARRES2 rs17173608 gene polymorphism and serum Chemerin with acute myocardial infarction (AMI) and its risk factors in an Iranian population. MethodsIn this case-control study, 134 AMI patients and 100 healthy controls were recruited from tertiary referral hospitals in Zanjan, Iran. Whole blood samples were collected for DNA extraction and Chemerin level determination. An enzyme-linked immunosorbent assay was used to quantify plasma levels of Chemerin. Tetra‐primer amplification refractory mutation system‐polymerase chain reaction and agarose gel electrophoresis techniques were used to detect gene polymorphism of Chemerin rs17173608 from DNA samples. ResultsSerum Chemerin levels were higher in the control group than in the AMI group. However, after adjusting for age, sex, and other risk factors, there was no significant association between serum Chemerin level and AMI occurrence. In the genotype analysis, 21.6% of patients had the TT genotype, and 78.4% had the TG genotype. The GG genotype was not detected in any patient. The genotype distribution of the healthy control group was 19.0% TT genotype, 80.0% TG genotype, and 1.0% GG genotype. Serum Chemerin levels in participants with TG genotype were statistically different between case and control groups. ConclusionSerum Chemerin levels and RARRES2 rs17173608 gene polymorphism were not correlated with AMI occurrence after adjusting for AMI risk factors in Iranian patients. More research with a larger sample size and diverse ethnicities is needed to corroborate our findings.

Adiponectin rs1501299 and chemerin rs17173608 gene polymorphism in children with type 1 diabetes mellitus: relation with macroangiopathy and peripheral artery disease.

Although macrovascular complications represent the leading cause of mortality in type 1 diabetes mellitus (T1DM), the prevalence of subtle macrovascular affection including peripheral artery disease (PAD) among children with T1DM and its genetic predictors remains to be unraveled. Increasing evidence suggests a link between adiponectin rs1501299 and chemerin rs17173608 gene polymorphism and atherogenesis, and insulin resistance. Hence, this study assess the prevalence of these variants among children with T1DM in comparison to healthy controls and their association with macrovascular complications, namely PAD and hyperlipidemia. Fifty children with T1DM and 50 matched controls underwent a thorough assessment including adiponectin rs1501299 and chemerin rs17173608 gene polymorphisms, fasting lipids, glycated hemoglobin (HbA1c), and ankle-brachial index (ABI). Cochran-Armitage trend test was used to decide the risk allele and evaluate the association between the candidate variant and PAD using a case-control design. Children with T1DM were found to have significantly higher ABI (p = 0.011) than controls. Chemerin gene polymorphism was detected in 41 children with T1DM (82.0%), while adiponectin gene polymorphism was detected in 19 children (38.0%). Children with T1DM having GG chemerin variant and those having TT adiponectin variant had significantly higher cholesterol with significantly lower HDL-C and ABI than those having the other two variants (p < 0.005). Children with T1DM having abnormal ABI had significantly higher chemerin G (p = 0.017) and adiponectin T (p = 0.022) alleles than those with normal ABI. Cholesterol and ABI were independently associated with chemerin and adiponectin gene polymorphism by multivariable regression analysis. Children with T1DM having chemerin and adiponectin gene polymorphisms have significantly higher cholesterol and ABI than those without these polymorphisms and controls. The Research Ethics Committee of Ain Shams University, approval number R 31/2021.

Association of the Adipokines Chemerin, Apelin, Vaspin and Omentin and Their Functional Genetic Variants with Rheumatoid Arthritis.

Adipokines were shown to exert crucial roles in rheumatic diseases. This study aimed to assess the role of chemerin, apelin, vaspin, and omentin adipokines and their genetic variants rs17173608, rs2235306, rs2236242, and rs2274907, respectively, in rheumatoid arthritis (RA) pathogenesis in Egyptian patients. A total of 150 RA patients and 150 healthy individuals were recruited. Blood samples were collected and used for genotyping. Serum was separated and used for expression analysis by quantitative PCR, and various biochemical markers determination by ELISA. Serum protein levels of chemerin and vaspin, as well as their gene expression levels were higher, while those of apelin and omentin were lower in RA patients and were associated with most of RA clinical and laboratory characteristics. G allele of chemerin rs17173608, T allele of vaspin rs2236242, and T allele of omentin rs2274907 were more frequent in RA patients. Serum levels and gene expression levels of chemerin in GG genotype carriers and vaspin in TT genotype group were significantly higher, while those of omentin in TT genotype carriers were significantly lower than RA patients with other genotypes. There was no association between apelin rs2235306 and RA. Chemerin rs17173608, vaspin rs2236242, and omentin rs2274907 polymorphisms were associated with increased susceptibility to RA.

Molecular basis of non-alcoholic fatty liver disease and metabolic syndrome in a subset of South Asians

Metabolic syndrome (MetS) and non-alcoholic fatty liver disease (NAFLD) are emerging threats in Pakistan. The prevalence of MetS is reported to be 18–46% in general population. Adipokines and their genetic polymorphisms are now considered as risk factors for these conditions. Chemerin modulates glucose and lipid homeostasis, nesfatin-1 acts as an anorexigenic peptide, desnutrin regulates adipose tissue fatty acid oxidation, adipocyte fat content, and size. Therefore, this study was designed to identify the molecular and genetic differences in the above-mentioned biomarkers in metabolic syndrome positive and negative individuals. This cross-sectional study was carried out at the Aga Khan University during October 2018 till August 2019. MetS positive (n = 92) versus negative (n = 208) adults aged between 18 and 50 years of age were recruited. MetS was diagnosed on the basis of National Cholesterol Education Program Adult Control Panel III criteria. Serum adipokine levels, lipid profile, blood glucose, and insulin were measured. Fatty liver was detected by ultra-sonographic scans. Chemerin rs17173608 polymorphism was determined by tetra-arm polymerase chain reaction. Higher chemerin (37.87 ± 13.60 vs. 24.03 ± 12.32 pg/ml), low desnutrin (103.08 ± 5.84;270.19 ± 25.67 pg/ml), and nesfatin levels (276.49 ± 31.09; 754.34 ± 57.77 pg/ml) were seen in Mets/NAFLD positive versus negative individuals, respectively. Serum chemerin showed a moderate positive correlation with MetS and fatty liver while desnutrin showed weak correlation with MetS, whereas nesfatin showed a moderate correlation with MetS and fatty liver (p < 0.05). Each unit increases in chemerin, and decrease in desnutrin was associated with higher odds of developing NAFLD (p < 0.05). The variant rs17173608 showed association with MetS phenotype (1.841 (1.101–3.078); p = 0.020). Presence of the minor “G” allele was seen to increase the risk of developing MetS by 1.567 (p < 0.012). High chemerin and low desnutrin are linked to fatty liver changes and MetS in a subset of local population. The presence of chemerin “G” allele increases the risk of developing MetS even further in the same individuals. Further studies are required for an in-depth analysis of the mechanism through which these biomarkers cause the effect.

DETECTIN OF VASPIN RS2236242 AND CHEMERIN RS17173608 GENE POLYMORPHSIMS IN A SAMPLE OF OBESE IRAQI POLYCYCTIC OVARY SYNDROME WOMEN

This study was performed to detect assess Vaspin rs2236242 and Chemerin rs17173608 gene polymorphisms with its association with susceptibility of obese PCOS in Iraqi women .Blood samples from 100 women with obese PCOS and 75 healthy control women matched in age and BMI were collected from AL-Yarmouk Teaching hospital during February2018-July 2018 were enrolled in case control study. Tetra amplification refractory mutation system‐polymerase chain reaction (T-ARMS-PCR) was performed to detect the adipokine SNPs in patients and healthy women under study. Results demonstrated a significant variations in either genotype distribution and alleles frequencies between the obese PCOS and healthy women regarding vaspin rs2236242 polymorphism. The T allele increased the PCOS risk in comparison with the A allele which was the protective against PCOS, as well clear positive correlation between rs17173608 SNP of chemerin and susceptibility of PCOS was identified also, and The T allele had related with elevated PCOS risk as in comparison to the G allele. Data from this work determined for the first time a significant association between vaspin and chemerin SNPs and susceptibility PCOS risk in Iraqi obese women especially T allele .To confirm our findings new studies with large sample size and different ethnicities must be required.

CHEMERIN IS AN INDISPENSABLE PRE-TREATMENT PREDICTOR OF SOFOSBUVIR, PEGYLATED INTERFERON-ALPHA AND RIBAVIRIN OUTCOMES IN CHRONIC HEPATITIS C EGYPTIAN PATIENTS

Chronic hepatitis C (CHC) treatment modalities dramatically evolve, however some patients still suffer treatment failure with sever aggressive side effects. Accordingly personalizing antiviral treatment becomes an urgent cornerstone in treatment path. Inflammation is one of the hallmarks of viral infection. Besides it is one of the main factors interfering with drug response. Accordingly, this study focused on studying some inflammatory markers interfering with antiviral response in different CHC patients. A cohort of 157 genotype 4 (G4) Egyptian CHC patients treated with sofosbuvir (SOF), pegylated interferon-alpha-2a (Peg-IFNα-2a) plus ribavirin (RBV) were enrolled. Single nucleotide polymorphism (SNP) within chemerin gene (rs17173608) was analyzed by quantitative real-time PCR (qRT-PCR). Serum chemerin, serum IL-6 and serum alpha-fetoprotein (AFP) were analyzed by enzyme-linked immunosorbent assay (ELISA). Fibrosis grade, serum AFP, serum IL-6 and serum chemerin levels were found to be significant univariant predictors of SOF, Peg- IFNα-2a and RBV response at (p < 0.01). Moreover, G/G Chemerin (rs17173608) genotype was also proved to be associated with treatment failure (OR=17.067- 95% CI =6.684-43.575- p < 0.001) in Egyptian CHC G4 patients. Combining all predictors in Multiple stepwise regression analysis concluded that higher serum chemerin levels and G/G Chemerin rs17173608 genotype formulated the strongest predictive model with a significant prediction capacity expressed by area under the receiving operating curve (AUROC) 0.881(95% CI = 0.832–0.931) with specificity of 77.1%, sensitivity of 80.2% and accuracy of 78.9%. Chemerin is a vital pretreatment predictor of anti-HCV drug response as it accurately predicts SOF, Peg- IFNα-2a and RBV different outcomes in naive Egyptian CHC G4 patients.

Chemerin rs17173608 Gene Polymorphism is not Associated with Type 2 Diabetes Mellitus: a Cross-sectional Study.

Previous studies have shown that chemerin has important roles in the development of obesity, insulin resistance, metabolic syndrome, polycystic ovary syndrome (PCOS) and T2DM. The main goal of our study was to investigate the role of Chemerin rs17173608 gene polymorphism in T2DM (type 2 diabetes mellitus). 100 patients with T2DM and 50 healthy volunteers were included in the present study. DNA isolation from blood samples was performed with K1820-02 DNA Mini Kit. Chemerin gene polymorphism was detected by Tetra- Amplification Refractory mutation system polymerase chain reaction (T-ARMS-PCR). At the end of T-ARMS-PCR, samples were run using gel electrophoresis. Some samples were validated by sequence analysis. In the genotype analysis, 18.0% of patients had TT genotype and 81.0% of TG genotype was detected. GG genotype was not detected in any patient. Genotype of 1 patient was unidentified. Genotype distribution of healthy control group was 12.0% TT genotype and 88.0% TG genotype. Similar to the T2DM group, the GG genotype was not detected in the control group. There was no statistically significant difference between T2DM group and healthy control group for TG and TT genotypes. To our knowledge, chemerin rs17173608 gene polymorphism has been investigated in T2DM for the first time herein. In the present study, the TT genotype ratios were higher in the T2DM subjects than in healthy subjects. G allele frequency in the T2DM group was lower than that in the control group. However, there was no statistically significant difference between the groups.

Association of Chemerin rs17173608 and Vaspin rs2236242 Polymorphisms with Type Two Diabetes Mellitus and its Impact on their Corresponding Serum Levels in Egyptian Population

Type-2 diabetes mellitus (T2DM) is an endocrine disease having a significant genetic component.

Chemerin rs17173608 and vaspin rs2236242 gene variants on the risk of end stage renal disease (ESRD) and correlation with plasma malondialdehyde (MDA) level

Introduction: End-stage renal disease (ESRD) is associated with critical kidney illness that seriously affects the lifespan. Genetic factors and oxidative stress could play critical role in the development of ESRD. We assessed the association between chemerin rs17173608 T/G and vaspin rs2236242 T/A genes variants with the risk of ESRD and their correlation with plasma malondialdehyde (MDA) level. Materials and methods: In a case-control study, 131 gender and age-matched unrelated healthy controls and 110 ESRD patients were enrolled. The chemerin rs17173608 T/G and vaspin rs2236242 T/A were detected by Tetra primer-amplification refractory mutation system-polymerase chain reaction (T-ARMS-PCR). The MDA concentration was determined by HPLC. Results: Our findings for the first time revealed that in codominant genetic model (T/G vs. T/T genotype), the T/G genotype of chemerin gene significantly had a protective role against ESRD susceptibility. Also, in the presence of chemerin G allele, the risk of ESRD decreased by 0.79-fold (p = .048) in Kurdish population of Iran. The MDA serum levels in ESRD patients carrying the chemerin T/G + G/G genotype of rs17173608 T/G and also in carriers of A/A + T/A genotype of vaspin rs2236242 T/A were significantly higher compared to those in control subjects. The overall distribution of vaspin rs2236242 T/A genotypes and alleles comparing ESRD patients and healthy subjects were not statistically significant. Conclusion: We found that the G allele of chemerin rs17173608 compared to T allele decreased the risk of ESRD, and there was a significant association between chemerin and vaspin variants with plasma MDA level in a sample of the Iranian population.

Association between chemerin rs17173608 and rs4721 gene polymorphisms and gestational diabetes mellitus in Iranian pregnant women

Gestational diabetes mellitus (GDM) is defined as hyperglycemia detected during pregnancy and its risk is increased with obesity. Chemerin, an adipokine, has been proposed as potential mediators of insulin resistance in GDM. This case-control study was designed to assess the relation between chemerin SNPs rs4721 (or rs10278590) and rs17173608 and the development of GDM. One hundred thirty GDM pregnant women with GDM and 160 healthy pregnant women were enrolled in this study. The diagnosis of GDM was based on the International Association of Diabetes and Pregnancy Study Group (IADPSG) criteria. Chemerin rs4721 polymorphism gene was amplified through PCR, and SNP was detected using restriction enzyme AluI. Genotyping for chemerin rs17173608 polymorphism was performed by using tetra-amplification refractory mutation system polymerase chain reaction (T-ARMS-PCR). Blood glucose level was measured by an enzymatic method. Our finding showed that the genotypes frequency of chemerin rs4721 polymorphism was significantly different between GDM and non-GDM groups (χ2 = 7.44, P = 0.02). The genotype of rs4721 was significantly associated with GDM in co-dominant and dominant genotypes (GG vs GT, OR = 2.3, 95%CI = 1.24–4.24, P = 0.008, and GG vs GT + TT, OR = 2.21, 95%CI = 1.23–3.99, P = 0.008, respectively). No significant difference was observed in allele frequency between case and control groups (P = 0.62). Moreover, the genotypes and allele frequencies of chemerin rs17173608 polymorphism did not show significant differences between GDM and non-GDM (P > 0.05). We concluded that the genotype of rs4721 was found to contribute significant risk to GDM while genotype of rs17173608 could not predict the risk of GDM.

Serum chemerin levels and chemerin rs17173608 genotypes in the susceptibility of diabetic nephropathy in Egyptian diabetic patients

Background Chemerin, a newly discovered adipokine, highly expressed in obese and insulin resistant patients may provide a link between chronic inflammation and metabolic syndrome. Aim Was to evaluate serum chemerin levels in diabetic nephropathy patients and to evaluate the susceptibility between rs17173608 chemerin gene polymorphism and diabetic nephropathy risk in Egyptian patients. Materials and methods Study was conducted on 105 patients having type 2 diabetes and twenty adult healthy matched controls. Patients were divided into three groups according to urinary albumin excretion (UAE), macroalbuminuric (UAE Results Serum chemerin level was significantly elevated in diabetic patients compared to controls. There is significant increase in serum chemerin levels among diabetic subgroups, significantly higher in diabetic patients with macroalbuminuria than in patients with microalbuminuria (P Conclusion Elevated serum chemerin could be marker of diabetic nephropathy and chemerin gene rs17173608 polymorphism is associated with susceptibility of diabetic nephropathy.

Association of chemerin Rs17173608 and vaspin Rs2236242 gene polymorphisms with metabolic syndrome in Egyptian women

Aim: The metabolic syndrome is a complex of interrelated risk factors for cardiovascular disease and diabetes. The adipokines, chemerin and vaspin, are known to have metabolic regulatory roles. This study aimed to assess the relation of chemerin rs17173608 and vaspin rs2236242 polymorphisms with metabolic syndrome and its related phenotypes in Egyptian women. Subjects and methods: The study included 100 healthy female subjects and 100 metabolic syndrome patients. The component traits of metabolic syndrome were determined and the genotypes of the polymorphisms were assessed using the tetra amplification refractory mutation system polymerase chain reaction procedure. Results: The minor G allele of the chemerin rs17173608 polymorphism had a significantly higher frequency in metabolic syndrome patients (p = 0.0001). The component traits of metabolic syndrome were significantly increased in the carriers of the GG and TG genotypes. In contrast, the rare A allele of vaspin rs2236242 polymorphism was significantly higher in the control subjects (p = 0.005). The carriers of the TA and AA genotypes showed significant relation with lower values of the phenotypes of metabolic syndrome. Conclusion: Metabolic syndrome in Egyptian females is associated with the minor allele of chemerin rs17173608 polymorphism, whereas the minor allele of vaspin rs2236242 polymorphism plays a protective role against metabolic syndrome.

Influence of chemerin rs17173608 polymorphism on polycystic ovary syndrome susceptibility

ObjectiveThe purpose of this study was to assess the association between the rs17173608 chemerin polymorphism and polycystic ovary syndrome risk (PCOS). Materials and methodsThis case–control study was performed on 150 patients with PCOS and 150 normal women as the control group. Tetra-amplification refractory mutation system–polymerase chain reaction was used to detect the polymorphism. ResultsOur finding showed a positive association between the chemerin gene rs17173608 polymorphism and risk of PCOS. In the dominant effect of the G allele (comparison between TG+GG and TT), TG+GG genotypes were associated with the risk of PCOS (odds ratio = 2; 95% confidence interval = 1.3–3.2, p = 0.003). The G allele is thus dominant and increases the risk of PCOS as compared to the T allele (odds ratio = 1.7, 95% confidence interval = 1.1–2.5, p = 0.009). Nonetheless, there was no significant association between chemerin rs17173608 gene polymorphism and PCOS after adjusting genotypes for body mass index and age. ConclusionThese results suggested that there was a significant association between chemerin rs17173608 polymorphism and the PCOS; but this relationship was affected by obesity status.

Association between chemerin rs17173608 polymorphism and obesity in Iranian women

Chemerin is a novel adipokine that regulates adipogenesis and adipocyte metabolism. Circulating levels of chemerin significantly correlated with body mass index (BMI) and obesity. In this study, we investigate the association of chemerin rs17173608 polymorphism and obesity risk. A total of 300 Iranian women was subjected to genotyping. Genotype determination was performed by tetra-amplification refractory mutation system-PCR (T-ARMS PCR) method. Our finding showed a significant association between GT (OR:2.8, 95% CI: 1.6-4.9, P<0.001) and GG (OR: 8.4, 95% CI: 2.1-33.8, P: 0.003) genotypes with overweight and obesity respectively. In the dominant genetic model (comparison of GT+GG vs. TT), GT+GG genotypes showed increased risk of overweight and obesity. Here we suggest that, for the first time, chemerin rs17173608 polymorphism is significantly associated with overweight and obesity in Iranian women.

Association between chemerin rs17173608 and vaspin rs2236242 gene polymorphisms and the metabolic syndrome, a preliminary report

Metabolic syndrome (MeS) is associated with increased risk for type 2 diabetes mellitus (T2DM) and cardiovascular disease. There is some evidence indicating that adipokines play a role in the development of MeS. The present study was aimed to investigate the impact of chemerin rs17173608 and vaspin rs2236242 gene polymorphisms with the risk of MeS in a sample of Iranian population.This case‐control study was done on 151 subjects with MeS and 149 without MeS, as defined by NCEP-ATPIII. Tetra amplification refractory mutation system‐polymerase chain reaction (T-ARMS-PCR) was designed to detect the polymorphisms. Our finding showed that there are significant differences in genotype frequencies between the groups regarding vaspin rs2236242 polymorphism (χ2=18.74, p<0.0001). A significant protection against MeS was found for vaspin rs2236242 in allele and genotypes (Odd Ratio [OR]=0.52; 95% confidence interval [CI]=0.37–0.72; p=0.0001, T vs A; OR=0.49; 95%CI=0.29–0.82; p=0.007, TT vs TA and OR=0.17; 95%CI=0.07–0.40; p<0.0001, TT vs AA). Our finding showed positive association between chemerin rs17173608 polymorphism and risk of MeS (χ2=7.70, p=0.021). The G allele increased the risk of MeS (OR=1.78; 95% CI=1.14-2.78; p=0.012) as compared to the T allele. In conclusion, our data suggest for the first time a significant association between vaspin rs2236242 and chemerin rs17173608 polymorphisms and the MeS in Zahedan, southeast Iran. Further studies with large sample size and different ethnicities are required to confirm our findings.